Aids

Two experimental HIV vaccine regimens failed to reduce infections in a 3-year trial in eastern and southern Africa compared with participants who were taking a placebo, some of whom were on oral PrEP, according to a study.

Researchers found that lenacapavir, an investigational long-acting antiretroviral drug, prevented 100% of new HIV infections among cisgender women in Africa who received injections every 26 weeks.

Three-quarters of people globally living with HIV are on ART, a roughly 30% increase during the last nine years, and fewer people acquired HIV in 2023 than at any point since the late 1980s, UNAIDS reported.

Long-acting injectable PrEP is feasible and acceptable to both men and women, according to a study presented at the AIDS 2024 meeting in Munich.

Lenacapavir, an injectable antiretroviral drug approved by the FDA for HIV treatment, prevented 100% of new HIV infections among women in a phase 3 trial in Africa, demonstrating its efficacy as PrEP, Gilead Sciences said.

The U.S. House of Representatives reauthorized the U.S. President’s Emergency Plan for AIDS Relief for 1 year as part of a spending package passed on Friday, sending the plan to the Senate for consideration.